Gilead Sciences, Inc.(NASDAQ : GILD)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
Health Technology » Biotechnology
|REGN||Regeneron Pharmaceuticals, Inc.||-0.58%||450.57||2.7%||$522.91m|
|VRTX||Vertex Pharmaceuticals, Inc.||-0.20%||212.55||1.9%||$515.41m|
|GILD||Gilead Sciences, Inc.||-2.21%||61.40||1.0%||$485.52m|
|BNGO||BioNano Genomics, Inc.||-2.89%||9.73||0.0%||$374.38m|
|ALXN||Alexion Pharmaceuticals, Inc.||-0.59%||152.75||2.0%||$371.25m|
|CRSP||CRISPR Therapeutics AG||-1.25%||125.69||0.6%||$292.02m|
|EXAS||EXACT Sciences Corp.||3.67%||136.12||18.4%||$252.07m|
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firms primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster, CA.